News ArticleGlaxoSmithKline Pharmaceuticals posts Rs. 33,462 lakh profit for Q2 FY2026, appoints new Ethics Head and auditor
Company reports Rs. 117,991 lakh revenue from operations for July-September 2026 and appoints Mr. Sandeep Seth as Head - Ethics & Compliance; Walker Chandiok & Co LLP proposed as new statutory auditors
GlaxoSmithKline Pharmaceuticals Limited released its unaudited standalone and consolidated financial results for the quarter and half year ended 30 September 2026. The company also appointed Mr. Sandeep Seth as Head - Ethics & Compliance and approved M/s Walker Chandiok & Co LLP as its new statutory auditors for FY 2027-28 to FY 2031-32, pending member approval.
GlaxoSmithKline Pharmaceuticals Limited
Change in Management
GlaxoSmithKline Pharmaceuticals Limited announced its unaudited financial results for the quarter and half year ended 30 September 2026, alongside key leadership and auditor appointments.
The company's standalone revenue from operations for the quarter ended 30 September 2026 stood at Rs. 117,991 lakh, with total income reaching Rs. 125,268 lakh.
Profit after tax for this quarter was Rs. 33,462 lakh, and Rs. 58,795 lakh for the half year ended 30 September 2026.
The Board approved the appointment of Mr. Sandeep Seth as Head - Ethics & Compliance effective from 3 November 2026. Mr. Seth has over 20 years of experience in ethics and compliance roles across pharmaceutical and healthcare sectors.
M/s Walker Chandiok & Co LLP has been recommended as the new statutory auditors for a five-year term starting from financial year 2027-28, subject to shareholder approval at the forthcoming Annual General Meeting.
Highlights
- Quarterly revenue from operations at Rs. 117,991 lakh for Q2 FY2026.
- Profit after tax of Rs. 33,462 lakh for the quarter and Rs. 58,795 lakh for H1 FY2026.
- Appointment of Mr. Sandeep Seth as Head - Ethics & Compliance from 3 November 2026.
- M/s Walker Chandiok & Co LLP appointed as new statutory auditors for FY 2027-28 to FY 2031-32, pending member approval.
Key Data Snapshot
What happened
- GlaxoSmithKline Pharmaceuticals approved unaudited standalone and consolidated financial results for Q2 and H1 FY2026 ending 30 September 2026.
- Reported revenue from operations for Q2 FY2026 was Rs. 117,991 lakh and total income Rs. 125,268 lakh.
- Profit after tax for Q2 FY2026 was Rs. 33,462 lakh and for H1 FY2026 Rs. 58,795 lakh.
- Appointed Mr. Sandeep Seth as Head - Ethics & Compliance effective 3 November 2026.
- Approved appointment of M/s Walker Chandiok & Co LLP as statutory auditors for five years starting FY 2027-28, subject to shareholder approval.
Key details
- Mr. Sandeep Seth brings over 20 years of experience in ethics, compliance and governance across pharmaceutical and healthcare sectors.
- Walker Chandiok & Co LLP is a well-established audit firm with multiple offices in India, registered with ICAI, PCAOB, and CAG.
- The company’s Board meeting took place on 3 November 2026 from 3:45 p.m. to 6:00 p.m.
- The statutory auditors' appointment is subject to approval at the company’s forthcoming Annual General Meeting.
Highlights
- Quarterly revenue from operations at Rs. 117,991 lakh for Q2 FY2026.
- Profit after tax of Rs. 33,462 lakh for the quarter and Rs. 58,795 lakh for H1 FY2026.
- Appointment of Mr. Sandeep Seth as Head - Ethics & Compliance from 3 November 2026.
- M/s Walker Chandiok & Co LLP appointed as new statutory auditors for FY 2027-28 to FY 2031-32, pending member approval.
Disclosures
- SEBI Listing Obligations and Disclosure Requirements Regulations, 2015
- SEBI Circular Nos. CIR/CFD/CMD/412015 dated 9 September 2015
- Exchange Circular List/Comp/14/2018-19 dated 20 June 2018
More News on Change in Management
View allLatest corporate announcements and market updates in Change in Management.
BPCL Director A.P.M. Mohammed Hanish Steps Down Effective 3rd November 2026
Bharat Petroleum Corporation Limited has announced that Shri A.P.M. Mohammed Hanish has ceased to be a director on the company's board effective 3rd November 2026, following a notification from the Government of Kerala regarding his reassignment.
Read Full Story
Zydus Lifesciences appoints Walker Chandiok & Co LLP as statutory auditors from FY 2026-2027 for five years
Zydus Lifesciences Limited announced on November 4, 2026, that its Board approved the appointment of Walker Chandiok & Co LLP as statutory auditors for a five-year term starting after the 32nd Annual General Meeting for financial year 2026-2027, subject to member approval.
Read Full Story
KFin Technologies Limited Shifts Corporate Office in Hyderabad Effective December 1, 2026
KFin Technologies Limited, acting as Registrar and Share Transfer Agent for HDFC Asset Management Company Limited, has notified the relocation of its corporate office to a new address in Hyderabad effective December 1, 2026.
Read Full Story
